Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastases

Abstract Tumor heterogeneity is a primary cause of treatment failure. However, changes in drug sensitivity over time are not well mapped in cancer. Patient-derived organoids (PDOs) may predict clinical drug responses ex vivo and offer an opportunity to evaluate novel treatment strategies in a person...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Kushtrim Kryeziu, Seyed H. Moosavi, Christian H. Bergsland, Marianne G. Guren, Peter W. Eide, Max Z. Totland, Kristoffer Lassen, Andreas Abildgaard, Arild Nesbakken, Anita Sveen, Ragnhild A. Lothe
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2021-09-01
Edice:	Journal of Translational Medicine
Témata:	Rectal cancer Liver metastasis Patient-derived organoid LCL161
On-line přístup:	https://doi.org/10.1186/s12967-021-03062-3
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!